Our development team works together with our computational chemists to design screening protocols according to the specificity of each project. Therefore, they define and optimize each parameter necessary for the successful project performance, and carefully select the most relevant data used in the process. Due to that design, we can retrieve the high-quality data from the massive databases, and continue to accelerate the drug discovery process and transform the existing R&D model.
At SOM Biotech, we use an exclusive approach combining our unique Artificial Intelligence-based technology, called SOMAI PRO, with the careful design and analysis performed by the specialists in molecular biology, biochemistry, and computational chemistry. As a result, it allows us to obtain a big list of high-quality lead candidate hits and targets. The whole process is cheaper, shorter, and more effective compared with a standard R&D process. Because of the individual approach, it can be applied to different therapeutic areas. Moreover, the platform and our work process were validated not only by a proper pipeline of SOM Biotech but also by our partners’ projects.
After the analysis performed by our Team employing our Artificial Intelligence-based technology, we do a detailed evaluation of obtained data, not only from scientific and medical points of view but also from the business perspectives. For experimental validation, our preclinical and clinical teams design each particular experiment necessary to analyze individual molecules. In all the process, we not only use the expertise of our team with diverse profiles, but we also rely on the opinion of the Key Opinion Leaders in each particular area.